Gradient Investments LLC Has $2.14 Million Stake in Novo Nordisk A/S (NVO)
Gradient Investments LLC grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 18.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,313 shares of the company’s stock after buying an additional 7,201 shares during the period. Gradient Investments LLC’s holdings in Novo Nordisk A/S were worth $2,136,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Zions Bancorporation purchased a new position in shares of Novo Nordisk A/S during the 1st quarter valued at about $137,000. Institutional & Family Asset Management LLC purchased a new position in shares of Novo Nordisk A/S during the 1st quarter valued at about $156,000. MV Capital Management Inc. purchased a new position in shares of Novo Nordisk A/S during the 1st quarter valued at about $185,000. Private Capital Group LLC lifted its position in shares of Novo Nordisk A/S by 2,357.1% during the 1st quarter. Private Capital Group LLC now owns 4,005 shares of the company’s stock valued at $200,000 after buying an additional 3,842 shares in the last quarter. Finally, Whittier Trust Co. lifted its position in shares of Novo Nordisk A/S by 61.5% during the 1st quarter. Whittier Trust Co. now owns 4,040 shares of the company’s stock valued at $199,000 after buying an additional 1,538 shares in the last quarter. 6.75% of the stock is currently owned by hedge funds and other institutional investors.
NYSE NVO opened at $48.21 on Tuesday. Novo Nordisk A/S has a 12 month low of $44.28 and a 12 month high of $58.37. The company has a market capitalization of $114.53 billion, a P/E ratio of 20.60, a price-to-earnings-growth ratio of 2.52 and a beta of 0.66.
A number of research firms have recently weighed in on NVO. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, July 31st. Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Monday, July 2nd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $64.00.
Novo Nordisk A/S Profile
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.
See Also: Marijuana Stocks
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.